Shares of Intra-Cellular Therapies (NASDAQ:ITCI) closed at $127.19, jumping $32.32 or 34.07%, on Monday, January 13, 2025, at 4:00 PM ET after Johnson & Johnson (NYSE:JNJ) revealed plans to acquire the biopharmaceutical company. The acquisition deal values ITCI at $132 per share in cash, representing a total value of approximately $14.6 billion.
Johnson & Johnson intends to fund the purchase with a mix of cash and debt, with the deal projected to close later this year, subject to regulatory and shareholder approvals. The acquisition boosts J&J's neuroscience portfolio, adding CAPLYTA (lumateperone), a drug approved for treating schizophrenia in adults, along with ITI-1284, a Phase 2 compound showing promise in addressing generalized anxiety disorder and Alzheimer's-related psychosis.
J&J plans to provide further details about the acquisition's effect on its adjusted earnings per share during its fourth-quarter earnings call later in January 2025.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.